Omadacycline Tosylate
FDA-approved product (tablet, oral), marketed as Nuzyra.
- Registered studies
- 0
- Lab records
- 1
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Bacterial pneumonia
- Skin disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Tetracyclines
- FDA pharmacologic class
- Tetracycline-class Antibacterial FDA label ↗
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01AA15; FDA class Tetracycline-class Antibacterial
Repurposing investigation
Omadacycline Tosylate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA86.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli79.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae97.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis61.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
- K. pneumoniae: measured active in 1 of 1 lab record
Show the 1 laboratory record, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Omadacycline Tosylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Micafungin SodiumExisting use: Candidiasis52.4% AI-predicted activityagainst E. coli50+ registered studies
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm52.3% AI-predicted activityagainst E. coli50+ registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- Ponatinib HydrochlorideExisting use: Acute lymphoblastic leukemia, Chronic myelogenous leukemia, Lymphoid leukemia and 1 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- FinerenoneExisting use: Cardiovascular disease, Chronic kidney disease, Type 2 diabetes mellitus52.2% AI-predicted activityagainst E. coli50+ registered studies
- Bromocriptine MesylateExisting use: Acromegaly, Adenoma, Hyperprolactinemia and 4 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma52.0% AI-predicted activityagainst E. coli50+ registered studies
- Edoxaban TosylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 3 more52.0% AI-predicted activityagainst E. coli22 registered studies
- PimecrolimusExisting use: Atopic eczema, Eczematoid dermatitis51.9% AI-predicted activityagainst E. coli50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia51.8% AI-predicted activityagainst E. coli4 registered studies
- TucatinibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 6 more51.6% AI-predicted activityagainst E. coli50+ registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more51.4% AI-predicted activityagainst E. coli14 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.